Russian Pharmaceutical Technologies Overview

  • Founded
  • 2012

Founded
  • Status
  • Private

  • Latest Deal Type
  • Grant

  • Latest Deal Amount
  • $292K

  • Investors
  • 1

Russian Pharmaceutical Technologies General Information

Description

Developer of drugs and therapies in field of oncology. The company develops, researches and commercializes new drugs and technologies in the field of oncology and medicine.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Angel-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
  • Griboyedov canal nab. 130
  • Liter A, Office 202
  • Saint Petersburg, 190121
  • Russia
+7 8 (000) 000-00-00

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Russian Pharmaceutical Technologies Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Grant 22-Jan-2014 $292K 000.00 Completed Startup
1. Angel (individual) 22-Jan-2014 000.00 000.00 Completed Startup
To view Russian Pharmaceutical Technologies’s complete valuation and funding history, request access »

Russian Pharmaceutical Technologies Patents

Russian Pharmaceutical Technologies Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-9957236-B2 Selective inhibitors interfering with fibroblast growth factor receptor and frs2 interaction for the prevention and treatment of cancer and other diseases Active 22-May-2014 0000000000 00
ES-2734649-T3 Selective inhibitors that interfere with the interaction of the fibroblast growth factor receptor and frs2 for the prevention and treatment of cancer and other diseases Active 22-May-2014 0000000000
JP-2017530111-A Selective inhibitors that interfere with the interaction of frs2 with fibroblast growth factor receptor for the prevention and treatment of cancer Granted 22-May-2014 0000000000
US-20170183315-A1 Selective inhibitors interfering with fibroblast growth factor receptor and frs2 interaction for the prevention and treatment of cancer and other diseases Granted 22-May-2014 0000000000 0
JP-6365999-B2 Selective inhibitors that interfere with the interaction of frs2 with fibroblast growth factor receptor for the prevention and treatment of cancer Active 22-May-2014 C07D239/42
To view Russian Pharmaceutical Technologies’s complete patent history, request access »

Russian Pharmaceutical Technologies Executive Team (2)

Name Title Board Seat Contact Info
Tamara Timofeeva Chief Executive Officer
Sergey Tulyandin Chief Scientific Officer
To view Russian Pharmaceutical Technologies’s complete executive team members history, request access »

Russian Pharmaceutical Technologies Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Skolkovo Foundation Limited Partner 000 0000 000000 0
To view Russian Pharmaceutical Technologies’s complete investors history, request access »